BASF Expands Innovation Campus Asia Pacific in Shanghai
BASF, the world’s leading chemical company, today broke ground on the second phase of its Innovation Campus Asia Pacific at its Pudong site in Shanghai, China. The €90 million expansion consists of an additional regional R&D building and auxiliary facilities and it will be completed by the end of 2015.
“By 2020, around 25% of BASF’s R&D employees will be located in Asia Pacific. The expansion reinforces BASF’s commitment to globalising its R&D activities and capturing growth opportunities in China and Asia Pacific,” said Dr Andreas Kreimeyer, member of the Board of Executive Directors of BASF SE and Research Executive Director.
The Innovation Campus is BASF’s most important R&D center in the region and is expected to become one of its largest R&D sites outside of Germany. With the expansion, BASF’s regional research capabilities will be further strengthened, focusing primarily on advanced materials and systems, as well as adding new areas such as formulations and chemical process and engineering serving growth industries such as automotive, construction, health and nutrition, and home and personal care.
“The Innovation Campus Asia Pacific in Shanghai has proven to be an effective platform that not only responds quickly to market needs in China and Asia Pacific, but also connects BASF with the science community in Asia Pacific. The enthusiasm for innovation among our colleagues, customers and partners is the cornerstone of solutions for a sustainable future in the region,” said Dr Martin Brudermüller, Vice Chairman of the Board of Executive Directors of BASF SE, responsible for Asia Pacific.
In Asia, in addition to the Innovation Campus in Shanghai, BASF also has R&D centers in Japan, Singapore and Korea. An Innovation Campus in India is also planned. BASF increased global spending on R&t to €1.8 billion in 2013 (2012: €1.7 billion), with around 10,650 scientists and researchers working in 3000 research projects. With 1300 patents filed last year and about 151,000 registrations and intellectual property rights worldwide, BASF is at the top of the global Patent Asset Index for the fifth time in succession.
Related News
-
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News CPHI Milan Speaker Spotlight: CDMO relations with Pharma and Start-Ups
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News Women in Pharma: Advocating for trans healthcare in pharma
In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance